Selera Synthetic Selenopeptide Designs for XP and Skin Cancer Treatment

Arthur Alves Coelho published a research paper on figshare in April 2026 detailing the design of five novel selenopeptides named Selera. The study used bioinformatic tools to evaluate physico-chemical properties and docking models with therapeutic targets like B-RAF and TrxR1. The work proposes a recombinant expression plasmid vector, p-Sec Reg 1, for future production.

Use Cases

• Evaluate peptide docking stability based on described low-binding energy levels and molecular dynamics profiles
• Design synthetic selenopeptides based on the described in silico optimization approach
• Analyze physico-chemical properties of novel peptide sequences like Selera-2

Strengths

• The study details five novel selenopeptide sequences designed and evaluated
• Docking analysis was performed with specific therapeutic targets B-RAF and TrxR1
• A new recombinant expression plasmid vector, p-Sec Reg 1, is proposed

Limitations

• The dataset is a single PDF document of 204.1 KB, which is a very limited scope
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

Arthur Alves Coelho

Collection Method

In silico optimization and bioinformatic tools

Freshness

Last updated 2026-04-09 04:07:40